Showing results (431-440 of 480) with videos related to
Sort By:
Pageof 48
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2015
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of CapecitabineJoyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJavier Cortes, Linda Vahdat, Joanne L Blum, et al.Archives of Women'S Mental Health|September 17, 2025
Effects of a Personalized Stress Management Intervention on Maternal Mental Health: A Randomized Clinical TrialS Darius Tandon, Judith T Moskowitz, Renee C Edwards, et al.The Oncologist|March 13, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA TrialSara A Hurvitz, Anthony Gonçalves, Hope S Rugo, et al.Lancet (London, England)|March 8, 2011
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortes, Joyce O'Shaughnessy, David Loesch, et al.Clinical Breast Cancer|December 17, 2008
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancerStephen Jones, Christopher Stokoe, Mark Sborov, et al.Cancer Medicine|April 22, 2026
Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS StudyDebu Tripathy, Joanne L Blum, Meghan S Karuturi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast CancerJoanne L Blum, A Douglas Laird, Jennifer K Litton, et al.Breast Cancer (Tokyo, Japan)|June 13, 2024
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational statusMelinda L Telli, Jennifer K Litton, J Thaddeus Beck, et al.Bioorganic & Medicinal Chemistry Letters|October 10, 2001
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approachR A Smith, J Barbosa, C L Blum, et al.Pageof 48